title: [Comparison of effects of two anticoagulants on hidden blood loss after total hip arthroplasty].
abstract: OBJECTIVE
  To compare the effects of rivaroxaban and enoxaparin on hidden blood loss after total hip arthroplasty (THA).
  
  
  METHODS
  A retrospective analysis was made on the clinical data of 76 patients (93 hips) with avascular necrosis of the femoral head who underwent primary THA between June 2009 and January 2012. After operation, 10 mg rivaroxaban was used at 6-10 hours for 14 days in 44 cases (54 hips) (rivaroxaban group) and 4 000 U enoxaparin at 12 hours for 14 days in 32 cases (39 hips) (enoxaparin group). There was no significant difference in age, gender, weight, height, disease duration, grade of avascular necrosis of the femoral head, and lesion hips between 2 groups (P > 0.05). The total blood loss, dominant blood loss, hidden blood loss, and percentage of hidden blood loss were calculated according to the formula. The bleeding events were recorded within 35 days after operation.
  
  
  RESULTS
  The total blood loss was (1 509.56 +/- 325.23) mL; the dominant blood loss was (928.09 +/- 210.50) mL; the hidden blood loss was (581.47 +/- 215.01) mL; and the percentage of hidden blood loss was 37.88% +/- 10.42% in the rivaroxaban group. The total blood loss was (1 521.38 +/- 516.49) mL; the dominant blood loss was (917.50 +/- 378.73) mL, the hidden blood loss was (603.88 +/- 377.15) mL, and the percentage of hidden blood loss was 38.18% +/- 18.33% in the enoxaparin group. There was no significant difference in the above indicators between 2 groups (P > 0.05). The incidence of bleeding event was 9.1% (4/44) in the rivaroxaban group and was 3.1% (1/32) in the enoxaparin group, showing no significant difference (Chi2=1.073, P=0.390).
  
  
  CONCLUSIONS
  There is no significant difference in the risk of hidden blood loss and incidence of bleeding event for primary THA between the rivaroxaban and the enoxaparin use.
authors.affiliation: Department of Orthopaedics, the Second Hospital, Anhui Medical University, Hefei Anhui, 230601, P.R.China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhou
authors.forename: Juehua
authors.initials: J
authors.lastname: Jing
authors.forename: Junfeng
authors.initials: J
authors.lastname: Zhan
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip; D016063:Blood Loss, Surgical / Q000517:prevention & control; D001810:Blood Volume; D017984:Enoxaparin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005271:Femur Head Necrosis / Q000601:surgery*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology*; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D019106:Postoperative Hemorrhage / Q000453:epidemiology / Q000517:prevention & control*; D012189:Retrospective Studies; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D017984:Enoxaparin; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban